Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Strontium”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 685 records · Page 38Linked to original sources

Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89.

Strontium-89 is an effective agent for palliation of pain due to bony metastases from breast and prostate carcinoma. As a functional analog of calcium, 89Sr is taken up by bone in areas of osteoblastic activity. Since patients with multiple myeloma frequently have osteolytic metastases, 89Sr might not be considered to be a therapeutic option. However, metastases which appear osteolytic by radiographs may demonstrate osteoblastic activity on bone scans. Consequently, the bone scan may be used to identify a subset of patients with osteolytic metastases who may benefit from 89Sr treatment. This report describes a patient with severe rib pain due to multiple myeloma whose chest radiograph showed multiple lucent lesions throughout the bones of the chest wall but whose bone scan showed marked osteoblastic activity. The patient was treated with 89Sr and received substantial pain relief. Bone scans may be useful in selecting myeloma patients or other cancer patients with osteolytic radiographic lesions who may benefit from 89Sr therapy.

Bone Neoplasms↗

Strontium, a tracer to study the transport of calcium in mineralizing tissues by electron probe microanalysis.

In growth plate cartilage the mineralization starts extracellularly in the lower hypertrophic zone. The mineral formed is the calcium phosphate apatite. Enough calcium and phosphate must be available at the mineralization front as well as in regions with proceeding mineralization. There must be a transport of Ca (and phosphate) to these sites. Electron probe X-ray microanalysis is a well established method to analyze element concentrations in small volumes, but it cannot discriminate isotopes. Strontium is similar to Ca in its chemical and biological behaviour and is therefore a suitable tracer to investigate the transport of Ca. Small amounts of Sr (0.1 g per kg body weight) were administered intraperitoneally to young rats. After definite intervals of time ranging from 10 to 120 min, 2-4 rats were killed. On freeze dried cryosections the Sr/Ca ratio of the serum and of the intra- and extracellular space of the growth plate were measured. The Sr/Ca ratio reaches its maximum after about 10 min in the serum and after 20 min in the extracellular space of growth plate cartilage. The intracellular Sr/Ca ratio shows large variations because of the low intracellular Ca and Sr concentration, and is lower than the extracellular ratio for times shorter than 30 min. No significant differences were found between the different cell zones of the unmineralized growth plate cartilage. The results demonstrate that the transport of Ca to the growth plate cartilage is relatively fast and that in growth plate cartilage, Ca is transported extracellularly, not intracellularly.

Animals↗

Accelerated ventricular escapes induced in the intact dog by barium, strontium and calcium.

Accellerated ventricular escapes (AVE) were produced with infusion of BaCl2, SrCl2 and CaCl2. AVE demonstrated overdrive acceleration rather than overdrive suppression, i.e., faster pacing rates caused shorter escape intervals. BaCl2 (mean 20.2 mumol/kg) produced AVE in 18 of 23 dogs and a decrease in mean serum potassium (K+). SrCl2 alone (mean 2494 mumol/kg) did not produce AVE in 5 dogs and K+ was unchanged. When insulin and glucose were infused to lower K+ and SrCl2 was infused 30 minutes later, AVE was demonstrated in 7 of 10 dogs. CaCl2 alone (mean 1628 mumol/kg) produced AVE in 3 of 5 dogs and CaCl2 (mean 1733 mumol/kg) infused 30 minutes after insulin and glucose produced AVE in 4 of 4 dogs. This study demonstrates that AVE previously produced with cardiac glycosides can also be induced by infusion of barium, strontium and calcium.

Animals↗

[The results of strontium-90 contact therapy to prevent the recurrence of pterygium].

AIM: Aim of the study was the evaluation of the role of adjuvant radiation therapy in the prevention of recurrence after excision. PATIENTS AND METHODS: Between July 1, 1985 and April 1, 1993, 64 patients (43 male, 21 female) were referred to radiation therapy after excision of a nasal pterygium. Radiation therapy was done with a strontium-90 eye applicator and a total dose of 30 Gy, fractionated in 6 fractions of 5 Gy each, 3 times a week. Forty-nine patients were treated primarily, 15 patients underwent radiation therapy for the first time in case of recurrent pterygium after multiple re-excisions. All patients had a following of 1 to 9 years with a median of 5.5 years. RESULTS: In 8 of 64 irradiated patients recurrent pterygium was detected (12.5%). Differentiated into the 2 groups 4 of the primarily treated patients had recurrent pterygium (8.16%), the other 4 were in the group with multiple former re-excisions (26.7%). With regard to the initiation of the irradiation after surgery pterygium did not recur in any of the primarily treated patients who were irradiated in between 3 days after surgery. In contrary 3 of 7 primarily treated patients (42.9%) who started radiation therapy between 7 and 10 days after surgery had recurrent pterygium. For the patients with primarily recurrent pterygium no dependence of the initiation of radiation therapy after surgery could be detected. CONCLUSIONS: Adjuvant radiation therapy after excision of pterygium lowers the rate of recurrence from about 40% to 12.5%, in a primarily adjuvant situation to 8.16%. In these patients radiation therapy should be initiated within 3 days after surgery. Patients with primarily recurrent pterygium have an elevated risk of recurrence independently of the initiation of radiation therapy.

Adult↗

Strontium-89 for treatment of painful bone metastasis from prostate cancer.

PURPOSE/OBJECTIVE: To review the current use of strontium-89 (89Sr) to treat pain related to bony metastasis secondary to prostate cancer. DATA SOURCES: Published articles. DATA SYNTHESIS: Prostate cancer is the most commonly diagnosed cancer in the United States. The disease's most common site of metastasis is the bones. Bone metastasis leads to unrelenting pain. If healthcare providers are able to manage a patient's pain successfully, the patient's quality of life improves. CONCLUSION: When conventional therapies fail, 89Sr can be used as an alternative or an adjunct to pain management of bony metastasis in prostate cancer. IMPLICATIONS FOR NURSING PRACTICE: Nursing intervention primarily involves assessing pain, monitoring analgesics until 89Sr can begin to take effect, educating patients on using other medications with 89Sr, and assessing fatigue resulting from 89Sr-induced myelosuppression. As pain decreases, nurses also should monitor patients' activity levels, since they are at risk for pathologic fractures.

Bone Neoplasms↗

[Imaging of strontium-89 uptake with bremsstrahlung using NaI scintillation camera].

Strontium-89 chloride is widely available in the U.S. and Europe for patients afflicted by bone metastasis associated with pain. 89Sr is a pure beta-emitter and it is thought to be difficult to estimate its distribution externally. We tried to image the distribution of 89Sr uptake with bremsstrahlung from beta-minus decay of 89Sr by using Nal scintillation camera. Pronounced 89Sr depositions in the bone metastatic sites were imaged in the energy windows from 50 keV to 150 keV bremsstrahlung. The distribution of these depositions corresponded to 99mTc-HMDP image may be suspected to the effectiveness of this therapy. The identification of 89Sr distribution might be useful in evaluating the bone marrow radiation dose too.

Aged↗

[Effectiveness of the radioactive strontium (89Sr) chloride agent, SMS.2P for pain palliation in patients with metastatic bone tumor in phase III multicenter clinical trial].

The phase III clinical trial of strontium-89 chloride agent (SMS.2P) was performed in 90 patients with painful bone metastases secondary to prostate (53), breast (18) and other types of cancer (19). Some patients experienced a transient increase in pain or nausea and vomiting. However both symptoms subsided and serious side effects were not observed in any of the patients. As reported, we confirmed some abnormal changes in peripheral blood picture. A decrease in the number of white blood cells and platelets was considered to be partly a result of bone marrow suppression due to 89Sr irradiation. Pain was substantially improved after 89Sr therapy in 58% of the patients and there was some alleviation in 12%. The release from pain was accompanied by an improved quality of life for these patients including sleep patterns and morbidity. Some patients were able to resume their former life styles. Most of the improved patients experienced pain relief from days to one week following 89Sr therapy and in half cases, this remained effective for 2 or 3 months. There were even cases in which the pain relief continued over an observation period of time of clinical study.

Adult↗

Results of histo-pathologic examination of three enucleated eyes with a choroidal melanoma after strontium-90 irradiation.

Three patients with a choroidal melanoma, treated with HDR (High Dose Rate) Strontium-90 brachytherapy, underwent an enucleation. Radiation effect was only visible at the irradiation zone with a brisk transition to normal tissue. Tumour was replaced by necrotic and scar tissue. The underlying sclera had a markedly reduced number of fibrocytes, but no structural alteration of the collagen stroma.

Aged↗

The efficacy of immunochemotherapy with strontium (Sr) in the 1,2-dimethylhydrazine (DMH) induced rat carcinogenetic model: ultrastructural characteristics of the mitochondria in the liver.

It is said that stable strontium (Sr), which exists naturally in living cells as a microelement, has cytoprotective effects on liver cells in mammals. We attempted to examine the cytoprotective and anticancer effects of Sr using the rat carcinogenetic model induced by DMH (1,2-dimethylhydrazine). In a comparison of animals given UFT, PSK and Sr or UFT and PSK, carcinogenes in the colon and also increases in immunosuppressive acidic protein (IAP) levels were suppressed. Electron microscopic observation in the Sr group revealed a tendency toward stabilization of the mitochondrial membrane and highly developed rough endoplasmic reticulum in both the right and left lobe. This tendency became more obvious as the duration of oral intake of Sr was prolonged. Our study suggest that the cytoprotective effect of Sr on mitochondria in the liver may suppress carcinogenesis.

1,2-Dimethylhydrazine↗

Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.

PURPOSE: Strontium-89 is currently used for the treatment of painful bone metastases. This study reports on two preliminary experiences with low-dose platinum compounds, carboplatin and cisplatin, as radiosensitizers in 89Sr therapy. PATIENTS AND METHODS: 30 patients entered the carboplatin study: 15 patients (Group A) were treated with 148 MBq 89Sr followed by carboplatin (100 mg/m2 at 7 and 21 days) and 15 patients (Group B) were treated with 89Sr alone. 12 patients entered the cisplatin study: six patients (Arm 1) received 148 Mq 89Sr plus cisplatin (50 mg/m2) in two administrations (immediately before and 10 days after 89Sr injection) and six patients (Arm 2) received 89Sr plus two placebo administrations. Pain response was assessed 8 weeks after the therapy on the Wisconsin score modifications. RESULTS: No clinically significant adverse effects or myelosuppression by platinum compounds were observed. In carboplatin study a pain response was observed in 20 of 27 (74%) evaluable patients, 13/15 in group A and 7/12 in group B. The pain response in the patients treated with 89Sr and carboplatin was clearly superior to that seen in the patients treated with 89Sr alone (P = 0.025), whereas survival was only marginally better in the combined treatment group (8.1 vs 5.7 months, P = 0.19). In cisplatin study a pain response was observed in 10 of 12 (83%) evaluable patients, 5/6 in Arm 1 and 4/6 in Arm 2. CONCLUSIONS: Low-dose platinum compounds seem to enhance the effects of 89Sr radioisotope therapy on pain from bone metastases without relevant hematological toxicity.

Bone Neoplasms↗

[Cellular mechanisms of postnatal growth of rat liver in during chronic exposure of cadmium sulfate and strontium chloride].

A cytophotometric investigation was performed to study the ploidy level and total protein content in hepatocytes of rats of different ages (1, 7, 14, 21, 30, 90, 180, 365 days), both intact and chronically treated with cadmium sulfate or strontium chloride. It was established that during the first month of postnatal ontogenesis, compositions of liver parenchyma cell population of intact and treated rats did not differ. Compared to control animals, the process of cell polyploidization in the liver of rats treated with heavy metal salts of 30-90 days proceeded slower, especially in Cd(2+)-treated rats. Within 180-365 days the cell polyploidization in the treated animals increased. The proportion of (4c x 2)-hepatocytes in 1 year old Cd(2+)- or Sr(2+)-treated rats increased, resp., by 2.7 and 1.5 times, and that of 8c hepatocytes was higher by 3.9 and 1.5 times than in the control, the average ploidy level rising by 20 and 5%. respectively. It was established that until 90 days the rate of protein accumulation in liver cells of intoxicated rats was slower than in intact animals. Thus, the average protein content per diploid hepatocyte in Cd(2+)- or Sr(2+)-treated 30 day old rats was lower by 20 and 16%, respectively, compared to control animals. The protein content increased in liver cells of Cd(2+)- or Sr(2+)-intoxicated rats following 90 and 180 days, respectively, and this process was exclusively associated with cell polyploidization. During the first 3 weeks after birth, no significant difference was observed in the extent of involvement of cell proliferation, polyploidization and hypertrophy in the growth of liver in intact and intoxicated animals. At this period the liver was growing due completely to cell proliferation and hypertrophy. During 21-30 days the contribution of cell proliferation to the liver growth of intact rats was not significant (29%), whereas it remained at higher level (50%) in the treated animals. In 30-90 days after birth, the involvement of proliferation process to the liver growth of intoxicated rats decreased to 25-28%, while in intact animals it increased up to 37%. At this period the cell polyploidization plays an essential role in the growth of liver in both intact and intoxicated animals to reach in average 37-46%. The contribution of polyploidization and hypertrophy to the liver growth of Cd(2+)-treated rats within 30-90 days was obviously higher than in Sr(2+)-treated animals. Both at the late (3-12 months) and at the early (1-21 days) stages of experiments, the pattern of correlation of different cell components in the growing liver of intact and intoxicated rats differed only a little.

Administration, Oral↗

Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.

GUIDELINE QUESTION: What is the role of strontium-89 in effective palliative care of patients with stage D endocrine-refractory prostate cancer and multiple sites of painful bone metastases? OBJECTIVE: To make recommendations about the routine use of 89Sr in this clinical setting. OUTCOMES: Effective palliation is the primary outcome of interest. Patient survival and toxic effects of treatment are also considered. PERSPECTIVE (VALUES): Evidence was selected and reviewed by 3 members of the Genitourinary Cancer Disease Site Group (Genitourinary Cancer DSG) of the Cancer Care Ontario Practice Guidelines Initiative. Earlier drafts of the guideline were circulated and reviewed by members of the DSG. The Genitourinary Cancer DSG comprises medical oncologists, radiation oncologists, urologists, a pathologist and a community representative. Guideline approval requires input from community representatives. QUALITY OF EVIDENCE: Three randomized controlled trials (RCTs) were available for evaluation. Two compared 89Sr with placebo, and one RCT compared 89Sr with conventional radiation (either hemibody or involved-field radiotherapy, as determined before randomization). BENEFITS: One of the 2 studies comparing 89Sr with placebo demonstrated the palliative efficacy of the intervention (p < 0.01); the other showed no benefit. The third study, comparing 89Sr with conventional radiation, concluded that all treatments provided equally effective pain relief and that improvement was sustained for at least 3 months in similar proportions of patients. The difference in the median duration of patient survival between groups in this study was neither clinically nor statistically significant. HARMS: The use of 89Sr may cause bone marrow suppression, but clinically significant sequelae are uncommon. The use of 89Sr may preclude further systemic chemotherapy or eligibility for clinical trials of systemic therapy. Symptoms other than those due to bone marrow suppression are rare. PRACTICE GUIDELINE: 89Sr is recommended for use in patients with endocrine-refractory prostate cancer who have multiple uncontrolled painful sites of bone metastases on both sides of the diaphragm not adequately controlled with conventional analgesic therapy, and in whom the use of multiple single fields of external beam radiation is not possible. 89Sr has proven to be efficacious in the palliation of hormone-refractory painful bone metastases from prostate cancer. It has not been shown to lengthen the average duration of patient survival. There is limited evidence on the relative efficacy of 89Sr compared with wide-field radiotherapy. 89Sr is the treatment of choice given all the following specific indications: Established diagnosis of prostate cancer metastatic to bone. Metastatic disease refractory to hormone therapy. Progressive sites of pain poorly controlled with conventional narcotics. Painful sites of disease on both sides of the diaphragm (otherwise, hemibody radiotherapy is equally efficacious). Patient or tumour factors (number of involved sites, location of involved sites or level of pain control) that are relative contraindications to the use of multiple single fields of radiation as an alternative. No evidence of impending spinal cord compression. Adequate bone marrow reserve. Evidence from a diagnostic bone scan of radionuclide concentration in painful bone lesions. PRACTICE GUIDELINE DATE: Nov. 23, 1997. Part 2. GUIDELINE QUESTION: What is the role of 89Sr in effective palliative care of patients with stage D hormone-refractory prostate cancer receiving involved-field radiotherapy for isolated painful bone metastases? OBJECTIVE: To make recommendations about the routine use of 89Sr in this clinical setting. OUTCOMES: Effective palliation is the primary outcome of interest. Patient survival and toxic effects of treatment are also considered. PERSPECTIVE (VALUES): As described in preceding abstract (Part 1). QUALITY OF EVIDENCE: One RCT was available for evaluati

Bone Marrow↗

Reversible bulk photorelease of strontium ion from a crown ether-linked merocyanine.

The use of a crown-ether-linked merocyanine, DCM-crown, for producing photoinduced, long-lived and reversible concentration jumps of metal cations is reexamined. In this new investigation, the excited-state behavior of DCM-crown complexed with a strontium ion in acetonitrile is found to exhibit the same trends as those previously reported with calcium and lithium ions. However, some new features provide evidence for cation photorelease to the bulk. Subpicosecond transient absorption experiments confirm the initial fast photodisruption of the interaction between the ion and the crown, and the formation of a loose complex after intramolecular charge transfer within the chromophore. Two additional steps are observed. Firstly, a continuous red shift of the gain spectrum is seen on the subnanosecond scale. It is assigned to the movement of the Sr2+ cation away from the chromophore, partly to the bulk of the solvent and partly towards the formation of an ultraloose complex with oxygen atoms of the crown. Secondly, a free-ligand-like absorption remains after the complete decay of the excited state. This band, which signals a total photorelease of the Sr2+ ion, disappears with a characteristic time of about 110 ns, attributed to the recomplexation of the crown in the ground state of the dye.

Journal Article↗

Laser-Excited Fluorescence Spectra of Strontium Monoiodide.

Fluorescence spectra of strontium monoiodide excited by Ar++ and Kr+ laser lines have been analyzed by Fourier transform spectrometry. Rotational levels have been populated either directly or after collisional relaxation: (i) in D2Sigma+ (v = 0, 1) by ultraviolet lines of Ar++, inducing numerous fluorescence transitions ending in the levels v = 0-3 of the strongly interacting A2Pi and B2Sigma+ states, (ii) in A2Pi3/2 (v = 0-4) by Kr+ line at 676.44 nm, de-exciting into transitions to X2Sigma+ (v = 0-6). Deperturbed constants for A2Pi and B2Sigma+ states and A approximately B interaction parameter are calculated from the numerical treatment of D2Sigma+ (v = 0, 1) --> A2Pi (v = 0-3) approximately B2Sigma+ (v = 0-3) transitions. Rotational constants for D2Sigma+ (v = 0, 1) are obtained for the first time. The wavenumbers of some 670 fluorescence lines are cataloged. Copyright 1999 Academic Press.

Journal Article↗

Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate.

Strontium ranelate (SR) is currently being developed for the treatment of osteoporosis. Pharmacologic studies in animal models have shown that its efficacy on bone mass is based on its original mode of action on bone formation and bone resorption. In normal mice, SR increased bone formation and vertebral bone mass. In normal rats, SR increased bone mass and the mechanical properties of vertebral, humeral and femoral bones, associated with increased femoral shaft diameter. Vertebral bone mineral density and bone strength were also increased by SR, whereas stiffness was not altered, underlining that the improvement in bone strength occurs without inducing defective bone mineralization. In normal adult monkey alveolar bone, SR decreased bone resorption and increased bone. In ovariectomized (OVX) rats, SR limited the reduction in bone mineral content and the decrease in trabecular bone volume induced by estrogen deficiency, by inhibiting bone resorption while maintaining bone formation. Curative treatment with SR also partially restored bone mass in OVX rats. In the model of hind limb immobilization in rats, SR reduced bone resorption and partially limited long bone loss, as assessed by bone mineral content, bone volume, and histomorphometric and biochemical indices of bone resorption. The unique mode of action of SR on bone formation and resorption is also supported by in vitro studies. In calvaria culture systems and osteoblastic cell cultures, SR enhanced the replication of preosteoblastic cells and consequently increased collagen synthesis. Moreover, SR inhibited the bone-resorbing activity of isolated mouse osteoclasts and devreased osteoclast differentiation markers in chicken bone marrow cultures. Altogether, these pharmacologic results suggest that SR optimizes bone metabolism by decreasing bone resorption and promoting bone formation, which may be of potential value in the treatment of osteoporosis.

Animals↗

Nanofibers of barium strontium titanate (BST) by sol-gel processing and electrospinning.

This paper describes the fabrication of barium strontium titanate (Ba0.6Sr0.4TiO3 or BST) nanofibers by electrospinning method using a solution that contained poly(vinylpyrrolidone) and a sol-gel solution of BST. The as-spun and calcined BST/PVP composite nanofibers were characterized by TG-DTA, X-ray diffraction, FT-IR, SEM and TEM, respectively. After calcination of the as-spun BST/PVP composite nanofibers at above 700 degrees C in air for 2 h, BST nanofibers of 188+/-25 nm in diameter having well-developed cubic-perovskite structure were successfully obtained. The crystal structure and morphology of the nanofibers were influenced by the calcination temperature. Calcination at below 700 degrees C resulted in amorphous phase whereas BST with second phase such as barium titanate were formed at above 700 degrees C. Diameters of the nanofibers decreased from 208+/-35 to 161+/-18 nm with increasing calcination temperature between 600 and 800 degrees C.

Journal Article↗

Preparation of barium strontium titanate Ba(1-x)Sr(x)TiO(3) (0<or= x <or=0.2) single-crystal nanorods by a novel combined method.

An ultrasonic irradiation method was applied to the sol/gel synthesis of the single-crystal cubic barium strontium titanate Ba(1-x)Sr(x)TiO(3) (0<or= x <or=0.2). The characteristics of the composites were examined by X-ray diffraction, thermogravimetric analysis, differential thermal analysis, transmission electron microscopy and high-resolution transmission microscopy. The diameters and lengths of typical resultant Ba(0.8)Sr(0.2)TiO(3) are in the range of 70-100 nm and 650-1000 nm, respectively. In addition, the stoichiometric sonogel formation and its heat-treatment process, the relationship between x of Ba(1-x)Sr(x)TiO (3) and the crystal structure, the relationship between synthesis condition of sonogel and morphology have been discussed.

Journal Article↗

Invertase production by Saccharomyces cerevisiae protoplasts immobilized in strontium alginate gel beads.

The invertase productivity of Saccharomyces cerevisiae IFO 0309 protoplasts in a static culture was 35 times (extracellular) and 9 times (extracellular + intracellular) higher than those of cells. When S. cerevisiae protoplasts were immobilized in 1.0% strontium alginate gel as an artificial cell wall, the protoplasts could be cultivated in a shake flask without disruption, and invertase was secreted into the broth. However, cell wall regeneration in the immobilized protoplasts was detected at about 24 h of cultivation. This implies that prevention of cell wall regeneration is a prerequisite for long term process with protoplasts. When 0.5 microg/ml aculeacin A (inhibitor of beta-1,3 glucan synthesis) was added to the broth, active protoplasts were maintained without cell wall regeneration for more than 24 h and invertase was produced extracellularly. Immobilized S. cerevisiae T7 protoplasts (this strain produces twice as much invertase as S. cerevisiae IFO 0309) were used for invertase production in a bubble column reactor, and a high and stable level of invertase (45 U/ml) was maintained for 72 h.

Journal Article↗